Attilio Bondanza

Attilio Bondanza is currently a member of the Board of Directors at Neogene Therapeutics, a position held since June 2025. Prior experience includes notable roles at AstraZeneca from January 2021 to May 2025, where Bondanza served as Vice President of Immunology Cell Therapy and Solid Tumour Cell Therapy, as well as Head of Cell Therapy, Early Development Oncology. At Novartis Institutes for BioMedical Research (NIBR) from January 2018 to December 2020, Bondanza was a Senior Clinical Program Leader for Cell and Gene Therapy, managing cross-functional teams and overseeing key projects in CAR-T therapy for lymphoma and leukemia. Additionally, Bondanza held academic positions as an Associate and Assistant Professor at Università Vita-Salute San Raffaele from October 2013 to September 2018, and contributed as a member of the Immunotherapy Working Group for the European Hematology Association from June 2016 to December 2017. Bondanza earned a Doctor of Philosophy (PhD) from Libera Università Vita-Salute San Raffaele and also trained as a Transplant Physician through JACIE - EBMT.